ArticleFrontiers in psychiatry2025
A network analysis of gene co-expression in post-mortem brain tissues identifying novel genes and biological pathways underlying major depression.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Shared molecular signatures linking gastroesophageal reflux disease and major depressive disorder revealed by integrated machine learning.BMC gastroenterology · 2026Article
- USP11 drives stress-induced synaptic structural deficits and depression-like behaviors through GSK3β/mTOR signaling.Neurobiology of stress · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Major Depressive Disorder (MDD), also known simply as depression, is a serious and common mood disorder. However, the potential pathogenesis and target genes of the disease have not been well illustrated. Methods: We identified differentially expressed genes(DEG) using the published transcriptome data GSE80655 from postmortem brain tissues of 69 MDD patients, 71 Bipolar Disorder (BD) patients, and 71 Schizophrenia(SZ) patients and 70 controls. Another brain expression dataset included geneexpression profiles from six cortical and limbic brain regions of 34 patients with MDD and 55 control subjects without any history of psychiatric or neurological disorders. GO enrichment analysis was performed on DEGs.Weighted gene Co-expression network analysis (WGCNA) was conducted on DEGs. Subsequently,we extracted the modules determined by WGCNA and calculated the correlation of the modules with diseases or brain tissue regions. The modules specifically related to MDD were screened. Module genes are employed for gene function enrichment analysis.Enriched genes in biological pathways are used to construct the gene regulatory network, and the genes with the highest connectivity are classified as hub genes. Results: DEGs related to MDD, BD, or SZ were screened. And by WGCNA, we determined the gene modules associated with MDD but not with BD and SZ. The MDD-related modules were further compared with the gene expression data from postmortem brain tissue of MDD patients in another group, and one of the gene modules which was enriched in the biological pathway related to mitochondrial oxidative phosphorylation and ubiquitination, was screened.Gene regulatory network analysis showed that the hub genes were PARK2, CUL1, SKP1, CYC1, and ATP5A1.The mitochondrial oxidative phosphorylation and ubiquitination related biological pathways are involved in the process of MDD. Discussion: The hub genes may provide possible candidates for MDD targeted therapy that is worth exploring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.